A global leader in discovering, developing, and bringing to market animal health vaccines and medicines, Zoetis (ZTS) focuses on livestock and companion animals. Zoetis’s products are sold in more than 100 countries, and it directly markets its products in about 45 countries.
Its well-diversified operations cover several core species such as cattle, poultry, sheep, and fish under livestock. Its operations also cover dogs, cats, and horses under companion animals. Thanks to Zoetis’ early efforts in emerging markets, it’s one of the leading players in animal health medicines and vaccines in countries such as Brazil, China, and Mexico.
These products cover five categories—vaccines, anti-infectives, parasiticides, medicated feed additives, and other pharmaceuticals. Due to the diversification and depth of Zoetis’ product portfolio, it can focus on its customers’ needs while addressing the varying requirements of different species and geographies. Across all its product categories, Zoetis has nearly 300 product lines.
Under other non-pharmaceutical categories, Zoetis’ products include nutritionals, agribusiness products, and products and services in the areas of biodevices, diagnostics, and genetics.
In this series, we’ll explore Zoetis’ (ZTS) financials, the performance of its key products and geographic segments, analysts’ recommendations for the stock, and the company’s valuation metrics.
In July, Zoetis acquired Abaxis for ~$2.0 billion at $83.00 per share. Abaxis is a leader in developing and commercializing diagnostic instruments for veterinary point-of-care services. This acquisition enhances Zoetis’ presence in veterinary diagnostics.
Next, we’ll look at Zoetis’s top line and its geographic performance.